2018-03-01Zeitschriftenartikel
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
Rondy, Marc
Kissling, Esther
Emborg, Hanne-Dorthe
Gherasim, Alin
Pebody, Richard
Trebbien, Ramona
Pozo, Francisco
Larrauri, Amparo
McMenamin, Jim
Valenciano, Marta
I-MOVE/I-MOVE+ group
Buda, Silke
Preuss, Ute
Prahm, Kerstin
Schweiger, Brunhilde
Wedde, Marianne
Heider, Alla
Martin, Maria
Biere, Barbara
Duerrwald, Ralf
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, −42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Files in this item
Thumbnail
eurosurv-23-9-1.pdf — Adobe PDF — 543.8 Kb
MD5: 46c89bb6c7af81eb4e5957d7d0d50672
Cite
BibTeX
EndNote
RIS
(CC BY 3.0 DE) Namensnennung 3.0 Deutschland(CC BY 3.0 DE) Namensnennung 3.0 Deutschland
Details